Curated News
By: NewsRamp Editorial Staff
May 12, 2026
NHS Rolls Out One-Minute Cancer Immunotherapy Jab
TLDR
- NHS roll-out of 1-minute pembrolizumab injection gives patients faster treatment, potentially improving outcomes and reducing costs.
- Pembrolizumab, previously given via hours-long infusion, is now administered as a quick subcutaneous injection, slashing administration time.
- Quick immunotherapy jabs make cancer treatment less burdensome, improving quality of life for thousands of NHS patients.
- Cancer patients now get a one-minute immunotherapy jab instead of hours-long IV drips, a huge time saver.
Impact - Why it Matters
This news matters because it represents a major improvement in patient experience and healthcare efficiency. The transition from lengthy intravenous infusions to a one-minute injection for pembrolizumab reduces hospital stay times, lowers treatment burden on patients, and allows the NHS to treat more patients with the same resources. It also signals a broader trend in oncology toward more convenient and less invasive administration methods, which could accelerate adoption of immunotherapies and improve outcomes for cancer patients worldwide.
Summary
The NHS in England is rolling out a treatment upgrade under which thousands of patients with cancer will now receive a one-minute injection of the immunotherapy pembrolizumab instead of having the drug administered via infusion as has been the case in the past. The jab slashes the administration time from hours to just a minute or two. This development marks a significant shift in cancer care, potentially improving patient experience and freeing up hospital resources.
For companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are also engaged in the development of innovative immunotherapies, this news underscores the growing momentum in the field. Calidi Biotherapeutics is focused on advancing stem cell-based platforms for cancer treatment, and the NHS's adoption of a faster administration method highlights the industry's push toward more efficient and patient-friendly therapies.
The news was covered by BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN. BMW focuses on the latest developments in biotechnology, biomedical sciences, and life sciences. The platform offers services including press release distribution via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, visit https://www.BioMedWire.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NHS Rolls Out One-Minute Cancer Immunotherapy Jab
